From Spinal Taps to Blood-Based Biomarkers: Advances in Alzheimer’s Testing
In this edition of Clinical Lab Chat, CLP’s Director of Business Intelligence, Chris Wolski, interviews Alessio Travaglia, PhD, PMP, director, Translational Science, Neuroscience, at the Foundation for the National Institutes of Health (FNIH).
The wide-ranging interview tackles all aspects of Alzheimer’s testing and treatment, including:
- Why traditional methods of Alzheimer’s testing are expensive, invasive, and limit access.
- The benefits of blood-based biomarkers for Alzheimer’s diagnosis.
- How better diagnostics will benefit patients.
- Why we’re on the cusp of a new golden age of neurology
- How more biomarkers fuel not only better diagnostics but better treatments.
More description
In this edition of Clinical Lab Chat, CLP’s Director of Business Intelligence, Chris Wolski, interviews Alessio Travaglia, PhD, PMP, director, Translational Science, Neuroscience, at the Foundation for the National Institutes of Health (FNIH).
The wide-ranging interview tackles all aspects of Alzheimer’s testing and treatment, including:
- Why traditional methods of Alzheimer’s testing are expensive, invasive, and limit access.
- The benefits of blood-based biomarkers for Alzheimer’s diagnosis.
- How better diagnostics will benefit patients.
- Why we’re on the cusp of a new golden age of neurology
- How more biomarkers fuel not only better diagnostics but better treatments.
2024-08-12
21 min
Listen elsewhere
Available Results
Generated results are saved to your library for reuse and search.
No generated results are available for this episode yet.
Transcript
No transcript is available for this episode yet.
Sign in to generate a transcript for review.
Sign in
Chapters
No chapters available.